Cathy has been involved in the healthcare industry for over 25 years working in a number of roles including market access leader in the biopharmaceutical industry, strategic advisor, and financial and market research consultant. She has experience in the areas of oncology, arthritis, multiple sclerosis, osteoporosis, ophthalmology, sepsis and several other therapeutic areas.
Among her significant accomplishments are managing and evolving several market access projects for blockbuster products including ENBREL and AVONEX . Cathy developed and implemented the market access launches for several market-leading products including FORTEO, XIGRIS, RAPAMUNE, and Norditropin. She also helped design and launch new Risk Minimization Action Plans (RiskMAPs) for Accutane (iPLEDGE), Revlimid (Revlimid Risk Evaluation and Mitigation Strategy), and Thalomid (Thalomid Risk Evaluation and Mitigation Strategy).
Cathy’s experience includes leadership roles at Covance (Vice President), Noblis, (Account Leader/Program Director) and APACHE Medical Systems, Inc./National Health Advisors (Principal).
She has the following degrees: M.H.S.A. at The George Washington University and B.A. Chemistry at Southern Methodist University.